Heightened long-term cardiovascular risks after exacerbation of chronic obstructive pulmonary disease

被引:15
|
作者
Hawkins, Nathaniel M. [1 ,7 ]
Nordon, Clementine [2 ]
Rhodes, Kirsty [2 ]
Talukdar, Manisha [3 ]
Mcmullen, Suzanne [4 ]
Ekwaru, Paul [4 ]
Pham, Tram [4 ]
Randhawa, Arsh K. [3 ]
Sin, Don D. [5 ,6 ]
机构
[1] Univ British Columbia, Ctr Cardiovasc Innovat, Div Cardiol, Vancouver, BC, Canada
[2] AstraZeneca UK Ltd, Cambridge, England
[3] AstraZeneca Canada Inc, Mississauga, ON, Canada
[4] Medlior Hlth Outcomes Res Ltd, Calgary, AB, Canada
[5] Univ British Columbia, UBC Ctr Heart Lung Innovat, Vancouver, BC, Canada
[6] Univ British Columbia, Dept Med Respirol, Vancouver, BC, Canada
[7] Univ British Columbia, St Pauls Hosp, Cardiol, 1081 Burrard St, Vancouver, BC, Canada
关键词
Heart Failure; Arrhythmias; Cardiac; Risk Factors; HEART-FAILURE; COPD; INFLAMMATION; STROKE;
D O I
10.1136/heartjnl-2023-323487
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectiveTo examine the risk of adverse cardiovascular (CV) events following an exacerbation of chronic obstructive pulmonary disease (COPD).MethodsThis retrospective cohort study identified patients with COPD using administrative data from Alberta, Canada from 2014 to 2019. Exposure periods were 12 months following moderate or severe exacerbations; the reference period was time preceding a first exacerbation. The primary outcome was the composite of all-cause death or a first hospitalisation for acute coronary syndrome, heart failure (HF), arrhythmia or cerebral ischaemia. Time-dependent Cox regression models estimated covariate-adjusted risks associated with six exposure subperiods following exacerbation.ResultsAmong 1 42 787 patients (mean age 68.1 years and 51.7% men) 61 981 (43.4%) experienced at least one exacerbation and 34 068 (23.9%) died during median follow-up of 64 months. The primary outcome occurred in 43 564 (30.5%) patients with an incidence rate prior to exacerbation of 5.43 (95% CI 5.36 to 5.50) per 100 person-years. This increased to 95.61 per 100 person-years in the 1-7 days postexacerbation (adjusted HR 15.86, 95% CI 15.17 to 16.58) and remained increased for up to 1 year. The risk of both the composite and individual CV events was increased following either a moderate or a severe exacerbation, though greater and more prolonged following severe exacerbation. The highest magnitude of increased risk was observed for HF decompensation (1-7 days, HR 72.34, 95% CI 64.43 to 81.22).ConclusionModerate and severe COPD exacerbations are independent risk factors for adverse CV events, especially HF decompensation. The impact of optimising COPD management on CV outcomes should be evaluated.
引用
收藏
页码:702 / 709
页数:8
相关论文
共 50 条
  • [21] Prevalence of deep venous thrombosis in patients with acute exacerbation of chronic obstructive pulmonary disease
    Duan Sheng-chen
    Yang Yuan-hua
    Li Xu-yan
    Liang Xiao-ning
    Guo Rui-jun
    Xie Wan-mu
    Kuang Tu-guang
    Dai Hua-ping
    Wang Chen
    CHINESE MEDICAL JOURNAL, 2010, 123 (12) : 1510 - 1514
  • [22] Temporal Risk of Nonfatal Cardiovascular Events After Chronic Obstructive Pulmonary Disease Exacerbation A Population-based Study
    Graul, Emily L.
    Nordon, Clementine
    Rhodes, Kirsty
    Marshall, Jonathan
    Menon, Shruti
    Kallis, Constantinos
    Ioannides, Anne E.
    Whittaker, Hannah R.
    Peters, Nicholas S.
    Quint, Jennifer K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209 (08) : 960 - 972
  • [23] Cardiovascular Risk in Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review
    Sa-Sousa, Ana
    Rodrigues, Cidalia
    Jacome, Cristina
    Cardoso, Joao
    Fortuna, Ines
    Guimaraes, Miguel
    Pinto, Paula
    Sarmento, Pedro Morais
    Baptista, Rui
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (17)
  • [24] Pulmonary Rehabilitation and Long-Term Physical Activity in the Chronic Obstructive Pulmonary Disease Patient
    Gimeno-Santos, Elena
    ARCHIVOS DE BRONCONEUMOLOGIA, 2019, 55 (12): : 615 - 616
  • [25] CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN PATIENTS WITH CORONARY HEART DISEASE WORSENS LONG-TERM PROGNOSIS AFTER PERCUTANEOUS CORONARY INTERVENTIONS
    Zafiraki, V. K.
    Kosmacheva, E. D.
    Mirzaev, S. G.
    Shulzhenko, L., V
    Ramazanov, J. M.
    Omarov, A. A.
    Imetova, Zh B.
    Pershukov, I., V
    KARDIOLOGIYA, 2021, 61 (11) : 24 - 32
  • [26] Long-term mortality in patients with chronic obstructive pulmonary disease following extracorporeal membrane oxygenation for cardiac assist after cardiovascular surgery
    Distelmaier, Klaus
    Niessner, Alexander
    Haider, Dominik
    Lang, Irene M.
    Heinz, Gottfried
    Maurer, Gerald
    Koinig, Herbert
    Steinlechner, Barbara
    Goliasch, Georg
    INTENSIVE CARE MEDICINE, 2013, 39 (08) : 1444 - 1451
  • [27] Long-Term Mortality and Medical Burden of Patients with Chronic Obstructive Pulmonary Disease with and without Subsequent Stroke Episodes
    Yen, Yu-Shu
    Harnod, Dorji
    Lin, Cheng-Li
    Harnod, Tomor
    Kao, Chia-Hung
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2020, 17 (07)
  • [28] Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease: a role for antiplatelet therapy?
    Harrison, Michelle T.
    Short, Philip
    Williamson, Peter A.
    Singanayagam, Aran
    Chalmers, James D.
    Schembri, Stuart
    THORAX, 2014, 69 (07) : 609 - 615
  • [29] Impact of Chronic Obstructive Pulmonary Disease on Long-Term Outcome in Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
    Zhang, Ming
    Cheng, Yun-Jiu
    Zheng, Wei-ping
    Liu, Guang-Hui
    Chen, Huai-Sheng
    Ning, Yu
    Zhao, Xin
    Su, Li-Xiao
    Liu, Li-juan
    BIOMED RESEARCH INTERNATIONAL, 2016, 2016
  • [30] Right heart failure as a risk factor for severe exacerbation in patients with chronic obstructive pulmonary disease: Prospective cohort study
    Orea-Tejeda, Arturo
    Grecia Navarrete-Penaloza, Ana
    Verdeja-Vendrell, Leslie
    Jimenez-Cepeda, Abril
    Gabriela Gonzalez-Islas, Dulce
    Hernandez-Zenteno, Rafael
    Keirns-Davis, Candace
    Sanchez-Santillan, Rocio
    Velazquez-Montero, Alejandra
    Puentes Rodriguez, Gerardo
    CLINICAL RESPIRATORY JOURNAL, 2018, 12 (12) : 2635 - 2641